We report a patient with coexistence of multiple myeloma and preceding essential thrombocythemia (ET) who underwent successful stem cell mobilization and autologous hematopoietic cell transplantation. A 54-year-old Caucasian woman was diagnosed with Durie-Salmon stage 3A multiple myeloma in 2009. Thirteen years prior to the myeloma presentation, she developed myocardial infarction for which she underwent angioplasty and coronary artery stenting. She was started on ticlopidine; however, she developed thrombotic thrombocytopenic purpura with associated renal failure. She received plasmapheresis and short-term hemodialysis with eventual resolution of renal failure. Ten years prior to the myeloma presentation, she was diagnosed with ET with reported platelet counts in the 800 Â 10 3 /mL range. Bone marrow biopsy showed hypercellular marrow (70% cellularity) with an increased number of megakaryocytes and hyperlobation, hyperchromasia and separated nuclei. She had undergone vascular surgeries as well as thrombolysis and anticoagulation with warfarin for peripheral arterial disease. Her ET was managed with hydroxyurea for 5 years prior to myeloma presentation.
One year prior to the diagnosis of myeloma, she suffered a vertebral fracture following trauma requiring kyphoplasty of the T11 vertebra. Subsequent workup revealed mild hypercalcemia with calcium of 10.7 mg/dL (upper limit of normal: 10.2 mg/dL). Serum protein electrophoresis did not detect monoclonal protein but serum immunofixation electrophoresis showed kappa light chain. Urine protein electrophoresis showed 11 mg/24 h of kappa free light chain. A bone marrow biopsy was performed, which showed 70% kappa-restricted plasma cell involvement. Cytogenetics showed a normal female karyotype and a myeloma FISH panel was normal. Skeletal survey showed multiple vertebral compression fractures. She was treated with a combination regimen of lenalidomide, bortezomib and dexamethasone. Bone marrow biopsy after eight cycles of chemotherapy showed less than 1% polyclonal plasma cells by flow cytometry and marked megakaryocytic hyperplasia, consistent with complete response from the myeloma standpoint; but with an ongoing chronic myeloproliferative neoplasm. She was found to harbor the JAK2 V617F mutation at 10% allele burden. Pre-transplant platelet count ranged from 334 Â 10 3 to 444 Â 10 3 /mL (normal range, 143 to 382 Â 10 3 /mL). The patient underwent successful stem cell mobilization with granulocyte-colony stimulating factor. She underwent high-dose chemotherapy with melphalan at 200 mg/m 2 followed by autologous hematopoietic cell transplantation for consolidation. She received 3.81 Â 10 6 CD34 þ cells/kg on day 0. The patient achieved neutrophil and platelet engraftment on day þ 11 and þ 18, respectively. Two years after the transplant, the patient remains in complete response for myeloma without maintenance therapy. Maintenance therapy for myeloma was not prescribed due in part to the thromboembolic risks associated with immunomodulatory agents in addition to the underlying risk from ET. She achieved clinicohematologic response for ET with decreased normalization in her platelet count ( Figure 1 ) and has been free of anticoagulation. Post-transplant JAK2 V617F mutation allele burden was 18% at the 1st month, 10% at the 3rd month, and subsequent values showed slow but steady increment over time up to 20% at 2 years ( Figure 1) .
Concurrent existence of both multiple myeloma and ET in the same patient appears to be a rare association and review of the literature discloses fewer than 20 cases published thus far.
1,2 Some reports suggested the temporal association between cytotoxic chemotherapy (including hydroxyurea) for the treatment of ET and the later development of myeloma or plasma cell leukemia, as was noted in our patient.
1-3 JAK2 V617F mutation is seen in approximately half of the patients with ET. 4 The presence of JAK2 mutation in our patient is presumed to derive from persistent ET and not from myeloma, as no studies have convincingly demonstrated the presence of JAK2 V617F mutation in multiple myeloma; 5, 6 however, the role of JAK-STAT signaling in myeloma cell survival and proliferation has been implicated and ongoing in vivo studies are presently evaluating methods to inhibit the JAK-STAT pathway as a future treatment strategy for myeloma.
Holtan et al. 7 reported a patient with multiple myeloma and concomitant JAK2-positive ET who received successful autologous hematopoietic cell transplantation. In contrast to the previous report, this is the first report of longitudinal monitoring regarding the JAK2 V617F mutation allele burden after autologous hematopoietic cell transplantation in a patient with concurrent multiple myeloma and ET. The burden of JAK2 mutation decreased temporarily after transplant, although, it has been steadily rising as, not surprisingly, the treatment strategy is not curative for myeloproliferative neoplasm. However, high-dose melphalan and autologous hematopoietic cell transplantation remains a viable treatment option for patients with coexistent multiple myeloma and ET, in particular to manage plasma cell neoplasm and decelerate disease progression.
